Pipeline

OXU-005 mob

OXU-005 is a potential first-in-class, long-lasting treatment for diabetic retinopathy. OXU-005 contains a proprietary narrow spectrum kinase inhibitor with potent anti-angiogenic and anti-inflammatory properties. OXU-005 will be prepared using long-lasting Oxuspheres and is designed to be delivered via Oxulumis to the posterior suprachoroidal space. Preclinical studies with OXU-005 demonstrate encouraging efficacy compared to benchmark clinical …

OXU-005 mob Read More »

OXU-001 mob (DME)

OXU-001 is being developed to provide retinal specialists with a potent, long-lasting, safe, and broad-acting anti-edema and anti-inflammatory for the treatment of DME, RVO and uveitis. Given this product profile, there is potential to expand OXU-001 development to radiation maculopathy and specifically to radiation-induced macular edema. OXU-001 are dexamethasone-containing Oxuspheres that are designed to be …

OXU-001 mob (DME) Read More »

OXU-003

OXU-003 is a potential first-in-class registered treatment for retinoblastoma. OXU-003 is an innovative stable, sustained-release preparation of a proprietary chemotherapy agent. It is designed to be safely delivered in the suprachoroidal space, adjacent to primary retinoblastoma tumors using Oxulumis microcatheter. Once delivered, OXU-003 is designed to release the anti-cancer drug over prescribed treatment cycles. The …

OXU-003 Read More »

OXU-001 (DME)

OXU-001 is being developed to provide retinal specialists with a potent, long-lasting, safe, and broad-acting anti-edema and anti-inflammatory for the treatment of DME, RVO and uveitis. Given this product profile, there is potential to expand OXU-001 development to radiation maculopathy and specifically to radiation-induced macular edema. OXU-001 are dexamethasone-containing Oxuspheres that are designed to be …

OXU-001 (DME) Read More »

OXU-005

OXU-005 is a potential first-in-class, long-lasting treatment for diabetic retinopathy. OXU-005 contains a proprietary narrow spectrum kinase inhibitor with potent anti-angiogenic and anti-inflammatory properties. OXU-005 will be prepared using long-lasting Oxuspheres and is designed to be delivered via Oxulumis to the posterior suprachoroidal space. Preclinical studies with OXU-005 demonstrate encouraging efficacy compared to benchmark clinical …

OXU-005 Read More »

Scroll to Top